NCT04182672

Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of FX006 in bursal injections and to assess the patient's impression to change in their chronic pain, following treatment.

Conditions

• Trochanteric Bursitis

Interventions

Type	Name	Description
DRUG	FX006	Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.

Timeline

• Start date: 2020-08-12
• Primary completion: 2022-12-14
• Completion: 2022-12-14
• First posted: 2019-12-02
• Last updated: 2024-01-02
• Results posted: 2024-01-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study